ArticleBioengineering (Basel, Switzerland)2025
Radiomics Analysis of Non-Enhancing Lesions After Bevacizumab Administration in Recurrent Glioblastoma.
Article in Bioengineering (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
This study explored radiomic features that help identify non-contrast-enhancing tumors (nCET) by analyzing regions where contrast-enhancing tumors (CET) transformed into nCET after Bevacizumab (BEV) treatment. The BEV cohort included 24 recurrent GBM (rGBM) patients treated with BEV, showing reduced contrast-enhancement on gadolinium-enhanced T1-weighted imaging (T1Gd) imaging. The 11C-methionine positron emission tomography (Met-PET) cohort consisted of 24 newly diagnosed GBM (nGBM) patients with available Met-PET data. VOIs were created from T2WI, FLAIR, T1Gd, and Met-PET to analyze nCET and T2/FLAIR lesions. After significant radiomic features were identified, a prediction model for nCET was developed in the BEV cohort and subsequently evaluated in the Met-PET cohort. A total of 37 and 46 significant radiomic features were found in the BEV and Met-PET cohorts, respectively. The key feature, T2WI_whole_GLCMcorrelation_1, was selected for predictive modeling. The model demonstrated high accuracy (AUC = 0.93,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.